PMC8312323_01
Medication strategy and disease conditions of the patient during the treatment. (A) An illustrated summary of the treatment received by the patient. (B) Course of tumor markers (carcinoembryonic antigen (CEA)) while receiving treatment.
OTT-14-4261-g0001.jpg
PMC8312323_01_OTT-14-4261-g0001.jpg
f0001
A 77-year-old man was diagnosed with stage IV (T1N3M1) lung ADC with right middle lobe, right-sided pleural effusion and multiple bone metastasis in June 2016 (Figure 1A). The patient achieved a stable disease (SD) of lung lesion, but a remarkable elevated level of serum carcinoembryonic antigen (CEA) was found (Figure 1B).